Atsushi Onodera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Atsushi Onodera has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Shinichiro Motohashi
Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
59 shared publications - Kiyoshi Hirahara
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
35 shared publications - Masahiro Kiuchi
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
34 shared publications - Motoko Y. Kimura
Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan
34 shared publications - Toshinori Nakayama
Department of Immunology, Graduate School of Medicine Chiba University Chiba Japan
34 shared publications - Ichita Hasegawa
Department of Experimental Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan
33 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Elsevier in Building and Environment
- Vol. 308
Performance evaluation of a positive-pressure ventilation system in a radiation protection shelter: Field experiment and computational fluid dynamics analysis
- 3 November 2026
- Published by Elsevier in Building and Environment
- Vol. 308
Open AccessPerformance evaluation of a positive-pressure ventilation system in a radiation protection shelter: Field experiment and computational fluid dynamics analysis
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eadx9864
Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eadx9864
Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.
- Open Access
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eadw1038
CD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells
Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eadw1038
Open AccessCD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells
Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes